Radiation Therapy in Addition to Gross Total Resection of Retroperitoneal Sarcoma Results in Prolonged Survival: Results from a Single Institutional Study

Table 1

Patient and tumor characteristics (all patients).

Parameter	No. of patients (%)
Sex
Male	11 (35%)
Female	20 (65%)
Age (range)	56 (20–83)
Race
Caucasian	28 (90%)
African American	3 (10%)
History of tobacco use	11 (35%)
Family history of malignancy	7 (23%)
Breast cancer	4 (13%)
Breast and ovarian cancers	2 (6%)
Sarcoma	1 (3%)
Prior cancer	4 (13%)
Breast	1 (3%)
Melanoma	1 (3%)
Hodgkin’s disease	1 (3%)
Prior radiation	3 (10%)
TNM stage
T2bN0M0	25 (81%)
T2bN0M1	4 (13%)
Desmoid	2 (6%)
Grade
1	6 (19%)
2	6 (19%)
3	17 (55%)
AJCC stage
I	10 (32%)
III	15 (48%)
IV	4 (13%)
Recurrent RPS	7 (23%)
Pretreatment size of RPS (range)	10.5 cm (4.0-20.0)
Histology
Leiomyosarcoma	15 (48%)
Liposarcoma	10 (32%)
Myxoid	3 (10%)
Dedifferentiated	4 (13%)
Desmoid	2 (6%)
Malignant fibrous histiocytoma	3 (10%)
Inflammatory myofibroblastic sarcoma	1 (3%)
CD 117 staining
Not done	16 (52%)
Negative	10 (32%)
Positive	5 (16%)
Imatinib mesylate given	1 (3%)
Symptoms at presentation
Pain/discomfort	20 (65%)
Weight loss (range)	9 (31%) 10–30 lbs
Early satiety/decreased appetite	6 (21%)
Nausea	3 (10%)
Change in menses	2 (7%)
Small bowel obstruction	2 (7%)